Earnings Insights · GE HealthCare Technologies (GEHC) · Q3 FY2026
GE HealthCare Technologies (GEHC) Q3 FY2026: GE HealthCare Q3 2026 Earnings: Margin Expansion and PCS Recovery Support Higher Guidance
By AlgovestIQ ResearchPublished
Read GE HealthCare Technologies’s results announcement (Form 8-K, filed Oct 28, 2026)
Key earnings findings
GE HealthCare Technologies (GEHC) Q3 FY2026 · results discussed on the earnings call · Form 8-K filed
- GE HealthCare Technologies reported Q3 FY2026 revenue of $5.51B against the $5.35B analyst estimate, a 3.0% beat, and EPS of $1.34 against the $1.20 analyst estimate, a 11.7% beat.
- Organic revenue grew 6.2%, ahead of the company’s full-year growth target, supported by growth across all three segments and a sharp operational recovery in Patient Care Solutions.
- GEHC closed at $75.82 on Oct 28, 2026, up 6.6% from $71.11 on Oct 27, 2026, the last close before the results were released.
Sources: GE HealthCare Technologies results announcement (SEC), the Q3 FY2026 earnings call, and AlgovestIQ reported-results and market data. All references
Did GE HealthCare Technologies beat earnings expectations?
- EPS has beaten the estimate in 2 of the most recent reported quarters.
- Revenue surprise across the last 8 reported quarters has ranged from -0.2% to 3.0%.
Reported figures against analyst estimates, compiled from AlgovestIQ data.
GE HealthCare reported third-quarter revenue of $5.5B, up 7.2% year over year, while diluted GAAP EPS rose 39.1% to $1.36 and adjusted EPS increased 25.1% to $1.34. Organic revenue grew 6.2%, ahead of the company’s full-year growth target, supported by growth across all three segments and a sharp operational recovery in Patient Care Solutions.
The central development was broader than the quarterly beat: GE HealthCare combined mid-single-digit orders growth, a record $23.7B backlog, margin expansion in every segment, and improved PCS execution to raise its full-year earnings outlook. The main qualification is that quarterly profitability and cash flow also benefited from lower net tariff costs and refunds, while inflation in memory components and oil-linked inputs remains an active offset.
Earnings Snapshot
| Metric | Reported | Change |
|---|---|---|
| Revenue | $5.5B | +7.2% |
| Organic revenue growth* | 6.2% | — |
| Organic orders growth* | 4.0% | — |
| Book-to-bill | 1.03x | — |
| Backlog | $23.7B | +12% |
| Net income attributable to GE HealthCare | $615M | +37.9% |
| Diluted GAAP EPS | $1.36 | +39.1% |
| Adjusted EBIT* | $913M | +19.9% |
| Adjusted EBIT margin* | 16.6% | +180 bps |
| Adjusted EPS* | $1.34 | +25.1% |
| Operating cash flow | $907M | +52.9% |
| Free cash flow* | $793M | +64.2% |
| Advanced Imaging Solutions revenue | $3.9B | +6.1% |
| Pharmaceutical Diagnostics revenue | $846M | +13.0% |
| Patient Care Solutions revenue | $793M | +8.5% |
\*Non-GAAP measure.
The Bigger Story
GE HealthCare’s quarter showed that its growth and margin improvement are becoming more balanced across the portfolio. Pharmaceutical Diagnostics remained the fastest-growing business, while Advanced Imaging Solutions delivered steady growth in its largest segment. More importantly, Patient Care Solutions returned to growth after supply and fulfillment problems weighed on its first-half performance.
PCS generated 8.8% organic revenue growth and expanded segment EBIT margin by 480 basis points to 8.6%. Management attributed the improvement to better supplier and factory execution, backlog conversion, and a more frequent operating-management cadence. The recovery matters because PCS had been the company’s weakest major segment earlier in the year.
Management also said it is evaluating strategic options for PCS. That review continues despite the departure of PCS President and CEO Jeannette Bankes, who will leave for a chief executive role at another public company. Neal Sandy, previously head of PCS Product Strategy and Management, will take over the segment on November 16.
Revenue and Operating Performance
Total revenue increased 7.2% to $5.5B, with 6.2% organic growth after excluding acquisitions and currency effects. Product revenue rose 6.7%, while service revenue increased 8.1%, providing a reasonably balanced contribution between equipment and the installed-base business.
Advanced Imaging Solutions
Advanced Imaging Solutions revenue increased 6.1% to $3.9B, or 4.5% organically. Growth came from CT, cardiovascular and interventional solutions, and surgical innovations.
Management said demand for cardiology products supported sales of AI-enabled CT systems, MR upgrades, and cardiovascular ultrasound. The company also cited continued investment in general imaging ultrasound, where it sees demand supported by staffing constraints, distributed care settings, and the need for noninvasive imaging.
AIS remains the largest source of revenue and backlog conversion. Its organic growth was below the company-wide rate, but its scale means execution in imaging will remain the largest determinant of overall growth.
Pharmaceutical Diagnostics
Pharmaceutical Diagnostics was the standout segment, with revenue up 13.0% to $846M and organic growth of 13.8%. Contrast media and radiopharmaceutical products both contributed.
Management described pharmaceutical diagnostics as a recurring-revenue business because agents are used for individual diagnostic scans and demand grows with procedure volumes. It also highlighted continued growth in radiopharmaceuticals, including Vercado, a cardiac PET tracer. Management said it delivered approximately 680 Vercado doses in the week ended October 23 and remains confident in its goal of reaching a $500M annualized exit rate by the end of 2028.
That target remains a management projection, not current revenue. Still, the growing radiopharmaceutical portfolio gives GE HealthCare a faster-growing business adjacent to its imaging equipment franchise.
Patient Care Solutions
PCS revenue increased 8.5% to $793M, or 8.8% organically. Improved product fulfillment in monitoring solutions and maternal-infant care was the principal driver.
Management said some monitoring-project installations that had shifted into the second half of 2026 are now converting into revenue. It also said that prior supply constraints have eased as the segment improved supplier coordination, production planning, and factory execution.
The fourth-quarter comparison will be less favorable. Management noted that PCS benefited from approximately $45M of revenue in the fourth quarter of 2025 from releasing a product hold, which will mute year-over-year growth in the upcoming period.
Profitability and Margins
GE HealthCare’s reported profitability improved materially. Net income attributable to the company rose to $615M from $446M, lifting net income margin by 250 basis points to 11.1%. Operating income increased to $805M from $653M.
Adjusted EBIT rose 19.9% to $913M, and adjusted EBIT margin expanded 180 basis points to 16.6%. Management attributed the gain to volume growth, pricing, cost productivity, and a favorable year-over-year net tariff impact. Those benefits were partly offset by inflation, including higher memory-chip costs and higher oil prices across the supply chain.
Margin improvement was broad based:
- AIS EBIT margin increased 130 basis points to 15.3%, driven by volume, price, and lower tariff expense.
- PDx EBIT margin rose 50 basis points to 29.9%, as volume and pricing offset planned investment in new products and the innovation pipeline.
- PCS EBIT margin expanded 480 basis points to 8.6%, primarily from higher volume and cost productivity.
The difference between GAAP and adjusted earnings is relevant. GAAP diluted EPS rose by $0.38 to $1.36, while adjusted EPS increased by $0.27 to $1.34. The reported tax rate declined to 17.1% from 27.8%, while adjusted ETR was largely stable at 22.0% versus 21.8%. The lower reported tax rate included discrete tax items, including a foreign tax audit settlement.
Adjusted earnings also exclude restructuring costs, acquisition-related charges, acquisition-intangible amortization, investment revaluation effects, and tariff refunds. The company excluded $9M of pre-tax tariff refunds from adjusted EBIT in the quarter.
Demand, Customers and Pricing
Organic orders increased 4.0%, producing a 1.03x book-to-bill ratio. Backlog ended the quarter at $23.7B, up $2.5B, or 12%, from a year earlier. Management said the trailing 12-month organic orders growth rate was 4.6%.
Management characterized orders as somewhat lumpy because large imaging contracts can shift between quarters based on timing. It nevertheless said the pipeline of opportunities increased and that fourth-quarter orders booked were tracking ahead of the third quarter.
Demand commentary was generally constructive. Management said it has not seen a meaningful slowdown in procedure-related indicators, including scan and contrast-use data. It also said imaging remains a priority category in customer capital budgets, while the installation funnel extends well into 2027 and 2028.
Pricing contributed to margin expansion, though management emphasized that pricing in healthcare equipment remains disciplined rather than unconstrained. It described a typical favorable pricing outcome as a 1% to 2% range, with greater opportunity where new products offer productivity or clinical differentiation.
Management also addressed component availability, particularly memory chips. It has entered multiyear agreements with technology suppliers to improve supply assurance and reduce volatility, but acknowledged that pricing for these inputs cannot necessarily be fixed for extended periods.
What Is GE HealthCare’s Guidance for Full-Year 2026?
GE HealthCare raised several elements of its 2026 outlook:
| Metric | Previous 2026 Guidance | Updated 2026 Guidance |
|---|---|---|
| Organic revenue growth* | 3.0% to 4.0% | Approximately 4.0% |
| Adjusted EBIT margin* | 15.4% to 15.7% | 15.5% to 15.7% |
| Adjusted ETR* | 20.0% to 21.0% | Reaffirmed |
| Adjusted EPS* | $4.80 to $5.00 | $4.95 to $5.05 |
| Free cash flow* | Approximately $1.6B | More than $1.6B |
\*Non-GAAP measure.
Management expects foreign exchange to provide an approximately 75-basis-point revenue tailwind for the full year. It said AIS and PDx should drive fourth-quarter growth, while PCS should grow sequentially but face a more difficult year-over-year comparison because of the 2025 product-hold release.
Management did not provide formal 2027 guidance. It said the order pipeline, record backlog, higher-margin product launches, pricing actions, and productivity programs provide a favorable setup, but also cautioned that tariffs and inflation remain moving variables.
Balance Sheet, Cash Flow and Capital
Third-quarter operating cash flow rose $314M to $907M, while free cash flow increased $310M to $793M. Both figures included a $55M tariff refund.
For the first nine months of 2026, operating cash flow was $1.4B and free cash flow was $973M. Working-capital demands remained meaningful: inventory increased by $430M and contract and other deferred assets increased by $265M during the nine-month period.
Cash, cash equivalents, and restricted cash totaled $2.9B at September 30, down from $4.5B at year-end 2025. The company had $10.0B of total debt outstanding and access to $3.5B in revolving credit facilities. Nine-month cash use included $2.3B for business acquisitions, $392M of capital expenditures and internal-use software, and $300M of share repurchases.
GE HealthCare also declared a quarterly dividend of $0.04 per share, a 14% increase from the prior quarter.
The company plans to acquire SOFIE Biosciences for $945M in cash, subject to regulatory approvals and other customary closing conditions. The transaction is expected to close in the first half of 2027. Management said SOFIE would add roughly 1% to total company revenue on an annualized basis and should grow at a low-double-digit rate in its first full year of ownership, with accretive adjusted EBIT margin and adjusted EPS.
What Investors Should Watch
1. PCS Execution After the Recovery
The third-quarter PCS rebound was significant, but investors should monitor whether improved fulfillment and margins persist through the more difficult fourth-quarter comparison. Sustained progress would support the view that the first-half weakness was primarily operational rather than demand-related.
2. Pharmaceutical Diagnostics Growth and SOFIE Integration
PDx remains GE HealthCare’s fastest-growing segment and a key source of recurring revenue. The planned SOFIE acquisition could deepen the company’s radiopharmaceutical supply-chain position, but investors should watch regulatory timing, deal completion, and evidence that the expanded footprint improves access and capacity.
3. Backlog Conversion and Orders Quality
A $23.7B backlog provides substantial revenue visibility, but the important question is conversion into revenue and margins. Orders growth of 4.0% remains healthy, though below revenue growth, making sustained pipeline strength important as the company enters 2027.
4. Margin Durability Amid Tariffs and Component Inflation
The third-quarter margin gain included favorable tariff comparisons and refunds. The company believes price, product mix, productivity, and supply-chain actions can offset future pressure, but memory-chip inflation and evolving trade policy remain risks to that outlook.
5. Strategic Direction for PCS
Management is continuing its strategic review of PCS. Any decision could alter GE HealthCare’s portfolio mix, capital allocation, and earnings profile, particularly because the segment is now showing improved operational performance.
AlgovestIQ Takeaway
GE HealthCare’s third quarter strengthened the case that its earnings recovery is becoming more operationally broad based. Organic revenue grew 6.2%, all segments expanded revenue and EBIT margins, and the company raised adjusted EPS and free-cash-flow guidance. The PCS recovery was particularly important after earlier supply and fulfillment problems.
Pharmaceutical Diagnostics remains the strongest growth engine. Its 13.8% organic growth, high 29.9% segment EBIT margin, and expanding radiopharmaceutical portfolio provide a more recurring complement to the company’s capital-equipment businesses. The planned SOFIE acquisition extends that strategy, although its benefits depend on a successful close and execution in a complex short-life radiopharmaceutical supply chain.
The unresolved issue is how much of the margin improvement can persist after favorable tariff comparisons and refunds fade. Management has identified price, productivity, improved product mix, and supply-chain actions as the offsets, but input inflation and tariff uncertainty remain material variables.
The investment case is increasingly centered on whether GE HealthCare can translate its record backlog, product cycle, and operational discipline into sustained mid-single-digit growth and continued margin expansion. Consistent PCS execution, durable PDx growth, and evidence that 2027 margins can rise despite tariffs and component costs would strengthen that thesis.
How did GEHC stock react?
GEHC closed at $75.82 on Oct 28, 2026, up 6.6% from $71.11 on Oct 27, 2026, the last close before the results were released.
| Session | Close | Change |
|---|---|---|
| Oct 27, 2026 (before release) | $71.11 | — |
| Oct 28, 2026 | $75.82 | +6.6% |
| Oct 29, 2026 | $76.42 | +7.5% |
Closing prices from AlgovestIQ market data. A move around a report also reflects the wider market.
More from this earnings season
- BSXBoston Scientific Q3 2026 Earnings: Cyberattack and Rhythm-Management Pressures Reset 2027 OutlookOct 28, 2026
- SYKStryker Q3 2026 Earnings: Orthopaedics Slowdown Overshadows Strong MedSurg GrowthOct 29, 2026
- DXCMDexcom Q3 2026 Earnings: Margin Expansion and U.S. Growth Offset Slower International SalesOct 29, 2026
- ABTAbbott Q3 2026 Earnings: Nutrition Spin-Off Overshadows Solid Underlying GrowthOct 21, 2026
- EWEdwards Lifesciences Q3 2026 Earnings: TAVR and TMTT Strength Drive Higher Full-Year OutlookNov 4, 2026
References
- Management commentary, analyst questions and outlook discussed on the call. Source: GE HealthCare Technologies Q3 FY2026 earnings call transcript, as of Oct 28, 2026.
- Reported results, segment figures and guidance from the company's results announcement. Source: GE HealthCare Technologies Form 8-K, Item 2.02 (SEC EDGAR), as of Oct 28, 2026.
- Reported revenue and EPS against analyst estimates, and the reported quarterly series. Source: AlgovestIQ reported-results data, as of Oct 28, 2026.
AI-generated analysis based on company-reported earnings data and earnings-call materials. Every reported figure is checked against GE HealthCare Technologies' earnings release and call transcript before publication. Not investment advice.